微卫星不稳定型子宫内膜癌的临床特点和治疗

doi:10.12280/gjszjk.20220442

摘要/Abstract

摘要：

子宫内膜癌（endometrial cancer，EC）近年发病率呈上升趋势，传统的病理组织分型不能精准地指导患者的个体化治疗及评估预后，基于分子生物学技术提出的EC分子分型应运而生，这种分子分型在EC患者术后放化疗、免疫治疗及靶向治疗中均具有重要的指导作用。其中，微卫星不稳定（microsatellite instability，MSI）型EC为癌症基因组图谱（The Cancer Genome Atlas，TCGA）分子分型中的一种，MSI型EC具有独特的临床特征和病理学特征，并且在治疗及预后方面也与其他分型的EC较为不同。分子分型现已整合到欧洲妇科肿瘤学会指南中，研究表明，MSI型EC患者化疗获益不高，但受益于免疫治疗，现已推荐使用免疫治疗联合抗血管生成药物治疗。目前关于MSI型EC患者的病理特点、预后和治疗方面仍存在一些争议，对MSI型EC患者的几项药物联合治疗仍在研究中，在EC患者中根据分子分型进行个体化治疗已成为研究的重点。

关键词: 子宫内膜肿瘤, DNA错配修复, 微卫星不稳定性, 免疫疗法, 预后

Abstract:

In recent years, the incidence of endometrial cancer (EC) has been on the rise, and the traditional pathological tissue typing cannot accurately guide the individual treatment and evaluate the prognosis of patients. The molecular typing of EC based on molecular biology technology came into being. This molecular typing has an important guiding role in postoperative chemoradiotherapy, immunotherapy and targeted therapy for EC patients. The microsatellite instability (MSI) type of EC is one of the molecular types of The Cancer Genome Atlas (TCGA). MSI type of EC has unique clinical and pathological features. In addition, it is different from other types of EC in terms of treatment and prognosis. Molecular classification has been integrated into the Guideline from European Society of Gynaecological Oncology. Recent studies have shown that the patients with MSI type of EC do not get more benefit from chemotherapy, but they can get benefits from immunotherapy. The immune therapy combined with anti-angiogenesis drugs therapy has been recommended for those patients. However, there are still some controversy on the pathological characteristics, prognosis and therapy of MSI type of EC. Several therapy protocols of the combined drugs are still under study. It is true that the individualized treatment according to the molecular classification of EC will be the research focus.

Key words: Endometrial neoplasms, DNA mismatch repair, Microsatellite instability, Immunotherapy, Prognosis

陈曦, 杨永秀. 微卫星不稳定型子宫内膜癌的临床特点和治疗[J]. 国际生殖健康/计划生育杂志, 2023, 42(1): 77-82.

CHEN Xi, YANG Yong-xiu. Clinical Characteristics and Treatment of Microsatellite Instability Type of Endometrial Cancer[J]. Journal of International Reproductive Health/Family Planning, 2023, 42(1): 77-82.

参考文献 41

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660 URL
[2]	Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer[J]. Lancet, 2022, 399(10333):1412-1428. doi: 10.1016/S0140-6736(22)00323-3. doi: 10.1016/S0140-6736(22)00323-3 pmid: 35397864
[3]	Markowska A, Chudecka-Głaz A, Pityński K, et al. Endometrial Cancer Management in Young Women[J]. Cancers(Basel), 2022, 14(8):1922. doi: 10.3390/cancers14081922. doi: 10.3390/cancers14081922
[4]	Cree IA, White VA, Indave BI, et al. Revising the WHO classification: female genital tract tumours[J]. Histopathology, 2020, 76(1):151-156. doi: 10.1111/his.13977. doi: 10.1111/his.13977 pmid: 31846528
[5]	Fanale D, Corsini LR, Scalia R, et al. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?[J]. Crit Rev Oncol Hematol, 2022, 170:103597. doi: 10.1016/j.critrevonc.2022.103597. doi: 10.1016/j.critrevonc.2022.103597 URL
[6]	Bounous VE, Robba E, Perotto S, et al. Gynecological Cancers in Lynch Syndrome: A Comparison of the Histological Features with Sporadic Cases of the General Population[J]. J Clin Med, 2022, 11(13):3689. doi: 10.3390/jcm11133689. doi: 10.3390/jcm11133689 URL
[7]	Bonneville R, Krook MA, Kautto EA, et al. Landscape of Microsatellite Instability Across 39 Cancer Types[J]. JCO Precis Oncol, 2017, 2017:PO.17.00073. doi: 10.1200/PO.17.00073. doi: 10.1200/PO.17.00073
[8]	León-Castillo A, de Boer SM, Powell ME, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy[J]. J Clin Oncol, 2020, 38(29):3388-3397. doi: 10.1200/JCO.20.00549. doi: 10.1200/JCO.20.00549 URL
[9]	Latham A, Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer[J]. J Clin Oncol, 2019, 37(4):286-295. doi: 10.1200/JCO.18.00283. doi: 10.1200/JCO.18.00283 pmid: 30376427
[10]	Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database[J]. Genet Med, 2020, 22(1):15-25. doi: 10.1038/s41436-019-0596-9. doi: 10.1038/s41436-019-0596-9 pmid: 31337882
[11]	Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance[J]. Gastroenterology, 2004, 127(1):17-25. doi: 10.1053/j.gastro.2004.03.068. doi: 10.1053/j.gastro.2004.03.068 pmid: 15236168
[12]	Møller P, Seppälä T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database[J]. Gut, 2017, 66(3):464-472. doi: 10.1136/gutjnl-2015-309675. doi: 10.1136/gutjnl-2015-309675 pmid: 26657901
[13]	Ryan N, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies[J]. JAMA Oncol, 2017, 3(12):1702-1706. doi: 10.1001/jamaoncol.2017.0619. doi: 10.1001/jamaoncol.2017.0619 pmid: 28772289
[14]	McMeekin DS, Tritchler DL, Cohn DE, et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study[J]. J Clin Oncol, 2016, 34(25):3062-3068. doi: 10.1200/JCO.2016.67.8722. doi: 10.1200/JCO.2016.67.8722 pmid: 27325856
[15]	Lynch HT, Snyder CL, Shaw TG, et al. Milestones of Lynch syndrome: 1895-2015[J]. Nat Rev Cancer, 2015, 15(3):181-194. doi: 10.1038/nrc3878. doi: 10.1038/nrc3878 pmid: 25673086
[16]	Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database[J]. Gut, 2018, 67(7):1306-1316. doi: 10.1136/gutjnl-2017-314057. doi: 10.1136/gutjnl-2017-314057 pmid: 28754778
[17]	Rossi L, Le Frere-Belda MA, Laurent-Puig P, et al. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study[J]. Int J Gynecol Cancer, 2017, 27(5):953-960. doi: 10.1097/IGC.0000000000000985. doi: 10.1097/IGC.0000000000000985 pmid: 28525912
[18]	Goodfellow PJ, Billingsley CC, Lankes HA, et al. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study[J]. J Clin Oncol, 2015, 33(36):4301-4308. doi: 10.1200/JCO.2015.63.9518. doi: 10.1200/JCO.2015.63.9518 pmid: 26552419
[19]	Gallon R, Gawthorpe P, Phelps RL, et al. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies[J]. Cancers (Basel), 2021, 13(3):406. doi: 10.3390/cancers13030406. doi: 10.3390/cancers13030406 URL
[20]	Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma[J]. Cancer, 2006, 106(1):87-94. doi: 10.1002/cncr.21560. doi: 10.1002/cncr.21560 pmid: 16323174
[21]	Wong A, Ngeow J. Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?[J]. Biomed Res Int, 2015, 2015:219012. doi: 10.1155/2015/219012. doi: 10.1155/2015/219012
[22]	Garg K, Shih K, Barakat R, et al. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset[J]. Am J Surg Pathol, 2009, 33(12):1869-1877. doi: 10.1097/PAS.0b013e3181bc9866. doi: 10.1097/PAS.0b013e3181bc9866 pmid: 19898223
[23]	Victoor J, Borght SV, Spans L, et al. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study[J]. Gynecol Oncol, 2021, 162(3):694-701. doi: 10.1016/j.ygyno.2021.06.030. doi: 10.1016/j.ygyno.2021.06.030 pmid: 34253388
[24]	Xiao JP, Wang JS, Zhao YY, et al. Microsatellite instability as a marker of prognosis: a systematic review and meta-analysis of endometrioid endometrial cancer survival data[J]. Arch Gynecol Obstet, 2022 Jun 4. doi: 10.1007/s00404-022-06636-8. Epub ahead of print. doi: 10.1007/s00404-022-06636-8
[25]	Evrard C, Alexandre J. Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian)[J]. Cancers(Basel), 2021, 13(10):2434. doi: 10.3390/cancers13102434. doi: 10.3390/cancers13102434
[26]	Bosse T, Nout RA, McAlpine JN, et al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups[J]. Am J Surg Pathol, 2018, 42(5):561-568. doi: 10.1097/PAS.0000000000001020. doi: 10.1097/PAS.0000000000001020 pmid: 29505428
[27]	Randall ME, Filiaci V, McMeekin DS, et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer[J]. J Clin Oncol, 2019, 37(21):1810-1818. doi: 10.1200/JCO.18.01575. doi: 10.1200/JCO.18.01575 pmid: 30995174
[28]	Resnick KE, Frankel WL, Morrison CD, et al. Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer[J]. Gynecol Oncol, 2010, 117(2):234-238. doi: 10.1016/j.ygyno.2009.12.028. doi: 10.1016/j.ygyno.2009.12.028 pmid: 20153885
[29]	Loukovaara M, Pasanen A, Bützow R. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer[J]. Cancer Med, 2021, 10(3):1034-1042. doi: 10.1002/cam4.3691. doi: 10.1002/cam4.3691 URL
[30]	Cherri S, Oneda E, Noventa S, et al. Microsatellite instability and chemosensitivity in solid tumours[J]. Ther Adv Med Oncol, 2022, 14:17588359221099347. doi: 10.1177/17588359221099347. doi: 10.1177/17588359221099347
[31]	Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up[J]. Radiother Oncol, 2015, 117(3):559-581. doi: 10.1016/j.radonc.2015.11.013. doi: 10.1016/j.radonc.2015.11.013 pmid: 26683800
[32]	Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma[J]. Int J Gynecol Cancer, 2021, 31(1):12-39. doi: 10.1136/ijgc-2020-002230. doi: 10.1136/ijgc-2020-002230 pmid: 33397713
[33]	Rousset-Rouviere S, Rochigneux P, Chrétien AS, et al. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology[J]. Biomedicines, 2021, 9(6):632. doi: 10.3390/biomedicines9060632. doi: 10.3390/biomedicines9060632 URL
[34]	Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial[J]. Gynecol Oncol, 2019, 155(3):406-412. doi: 10.1016/j.ygyno.2019.10.013. doi: S0090-8258(19)31596-3 pmid: 31677820
[35]	Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19(2):191-226. doi: 10.6004/jnccn.2021.0007. doi: 10.6004/jnccn.2021.0007 URL
[36]	Arora S, Balasubramaniam S, Zhang W, et al. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis[J]. Clin Cancer Res, 2020, 26(19):5062-5067. doi: 10.1158/1078-0432.CCR-19-3979. doi: 10.1158/1078-0432.CCR-19-3979 pmid: 32295834
[37]	Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2019, 20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. doi: S1470-2045(19)30020-8 pmid: 30922731
[38]	Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer[J]. N Engl J Med, 2022, 386(5):437-448. doi: 10.1056/NEJMoa2108330. doi: 10.1056/NEJMoa2108330 URL
[39]	Li A, Yi M, Qin S, et al. Prospects for combining immune checkpoint blockade with PARP inhibition[J]. J Hematol Oncol, 2019, 12(1):98. doi: 10.1186/s13045-019-0784-8. doi: 10.1186/s13045-019-0784-8 URL
[40]	Green AK, Feinberg J, Makker V. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer[J]. Am Soc Clin Oncol Educ Book, 2020, 40:1-7. doi: 10.1200/EDBK_280503. doi: 10.1200/EDBK_280503 pmid: 32213091
[41]	Bellone S, Roque DM, Siegel ER, et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability[J]. Cancer, 2022, 128(6):1206-1218. doi: 10.1002/cncr.34025. doi: 10.1002/cncr.34025 URL